Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-Data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)

Japanese Journal of Clinical Oncology

Volumn 45, Issue 7, 2015, Pages 670-676

  Miyauchi, Eisaku ^a   Inoue, Akira ^a   Kobayashi, Kunihiko ^b   Maemondo, Makoto ^c   Sugawara, Shunichi ^d   Oizumi, Satoshi ^e   Isobe, Hiroshi ^f   Gemma, Akihiko ^g   Saijo, Yasuo ^h   Yoshizawa, Hirohisa ⁱ   Hagiwara, Koichi ^b   Nukiwa, Toshihiro ^j  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Miyagi Cancer Center   (Japan)

^d SENDAI KOUSEI HOSPITAL   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f KKR Sapporo Medical Center   (Japan)

^g NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

ⁱ NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^j South Miyagi Medical Center   (Japan)

more..

Author keywords

EGFR; Gefitinib; Lung cancer; Mutation; Second line

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SECONDARY HEALTH CARE; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG ADMINISTRATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EXONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84941352736     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv054     Document Type: Article

References (16)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8.
3. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatinpaclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54-9.
4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010;2:121-8.
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012;13:239-46.
6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol 2011;12:735-42.
7. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
8. The NCCN Clinical Practice Guidelines in Oncology (version 4.2014). National Comprehensive Cancer Network, Inc. www.nccn.org (16 September 2014, date last accessed).
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
10. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
11. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
12. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.
13. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage III/IV patients with chemotherapy-naive NSCLC receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26: 2745-53.
14. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
15. Tseng JS, Yang TY, Chen KC, et al. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Onco Targets Ther 2014;23:799-805.
16. Fang S, Wang Z, Guo J, et al. Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Onco Targets Ther 2014;7:1185-93.